59.85
-0.11 (-0.18%)
-0.11 (-0.18%)
Upgrade to Real-Time
Afterhours (Closed)
Best deals to access real time data! |
|
Big Cap Pro
Monthly Subscription
for only
|
|
Small Cap Basic
Monthly Subscription
for only
|
|
Real-Time Alerts for Volume Breakouts, Highs and Lows for NYSE, NASDAQ, Amex, OTC Markets and OTCBB
Monthly Subscription
for only
|
|
VAT not included
|
| Company Name | Stock Ticker Symbol | Market | Type |
|---|---|---|---|
| Gilead Sciences Inc | GILD | NASDAQ | Common Stock |
| Price Change | Change Percent | Stock Price | Last Traded  |
|
|---|---|---|---|---|
| -0.11 | -0.18% | 59.85 | 19:59:40 |
| Close Price | Low Price | High Price | Open Price | Previous Close |
|---|---|---|---|---|
| 60.01 | 59.44 | 60.208 | 59.81 | 59.96 |
| Bid Price | Ask Price | Spread | News | |
|---|---|---|---|---|
| 59.75 | 59.95 | 0.20 | - | - |
| Stock Trades | Traded Volume | VWAP | Dollar Volume | Average Volume | 52 Week Range |
|---|---|---|---|---|---|
| 62,789 | 7,699,866 | $ 59.88 | $ 461,038,917 | 9,666,130 | 59.4001 - 89.00 |
| Last Trade Time | Type | Quantity | Stock Price | Currency |
|---|---|---|---|---|
| 19:59:40 | 67 | $ 59.77 | USD |
Gilead Sciences Financials
| Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
|---|---|---|---|---|---|---|
| $ 75.04B | 1.25B | 1.25B | $ 22.45B | $ 4.08B | 4.21 | 18.39 |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| - | $ 2.52 | 4.21% | - | - |
Gilead Sciences News
Loading Messages....
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical GILD Price Data
| Period † | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 60.59 | 63.64 | 59.4001 | 60.56 | 14,489,020 | -0.74 | -1.22% |
| 1 Month | 62.93 | 64.99 | 59.4001 | 62.08 | 9,925,203 | -3.08 | -4.89% |
| 3 Months | 72.09 | 72.1896 | 59.4001 | 64.74 | 9,293,380 | -12.24 | -16.98% |
| 6 Months | 79.90 | 87.66 | 59.4001 | 71.98 | 10,518,690 | -20.05 | -25.09% |
| 1 Year | 63.63 | 89.00 | 59.4001 | 72.00 | 12,859,291 | -3.78 | -5.94% |
| 3 Years | 75.01 | 89.54 | 59.4001 | 71.36 | 8,914,795 | -15.16 | -20.21% |
| 5 Years | 109.39 | 111.11 | 59.4001 | 75.19 | 8,988,899 | -49.54 | -45.29% |
Gilead Sciences Description
| Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite acquisition and pending Forty-Seven acquisition boost Gilead's exposure to cell therapy and noncell therapy in oncology. |
